[go: up one dir, main page]

DE69512219D1 - Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen - Google Patents

Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen

Info

Publication number
DE69512219D1
DE69512219D1 DE69512219T DE69512219T DE69512219D1 DE 69512219 D1 DE69512219 D1 DE 69512219D1 DE 69512219 T DE69512219 T DE 69512219T DE 69512219 T DE69512219 T DE 69512219T DE 69512219 D1 DE69512219 D1 DE 69512219D1
Authority
DE
Germany
Prior art keywords
targeted
egs
rnaase
rna
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69512219T
Other languages
English (en)
Other versions
DE69512219T2 (de
Inventor
Yan Yuan
Cecilia Guerrier-Takada
Sidney Altman
Fenyong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/207,547 external-priority patent/US5624824A/en
Application filed by Yale University filed Critical Yale University
Publication of DE69512219D1 publication Critical patent/DE69512219D1/de
Application granted granted Critical
Publication of DE69512219T2 publication Critical patent/DE69512219T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69512219T 1994-03-07 1995-03-07 Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen Expired - Fee Related DE69512219T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/207,547 US5624824A (en) 1989-03-24 1994-03-07 Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US08/215,082 US5728521A (en) 1989-03-24 1994-03-18 Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
PCT/US1995/002816 WO1995024489A1 (en) 1994-03-07 1995-03-07 Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences

Publications (2)

Publication Number Publication Date
DE69512219D1 true DE69512219D1 (de) 1999-10-21
DE69512219T2 DE69512219T2 (de) 2000-01-20

Family

ID=26902350

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69512219T Expired - Fee Related DE69512219T2 (de) 1994-03-07 1995-03-07 Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen

Country Status (8)

Country Link
US (2) US5869248A (de)
EP (1) EP0748383B1 (de)
JP (1) JPH10508181A (de)
AT (1) ATE184649T1 (de)
AU (1) AU696138B2 (de)
CA (1) CA2185117A1 (de)
DE (1) DE69512219T2 (de)
WO (1) WO1995024489A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US5976874A (en) * 1996-08-16 1999-11-02 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
US8293224B2 (en) * 2000-02-07 2012-10-23 Trustees Of Dartmouth College Attenuated uracil auxotroph of an apicomplexan and use thereof
WO2001092463A2 (en) * 2000-05-31 2001-12-06 Istituto Di Biologia Cellulare, Cnr Method of rna cleavage
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2425779C (en) 2000-10-12 2013-08-06 University Of Rochester Compositions that inhibit proliferation of cancer cells
MXPA04007586A (es) 2002-02-06 2005-06-08 Vicor Technologies Inc Moleculas anti-infarto.
AU2003253580A1 (en) * 2002-02-26 2003-11-17 University Of Minnesota Variants of nedd4l associated with hypertension and viral budding
AU2003223775A1 (en) * 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
US20030215815A1 (en) * 2002-05-20 2003-11-20 Clark William G. Screening method
US20030215872A1 (en) * 2002-05-20 2003-11-20 Clark-Mxr, Inc. Screening apparatus and method for making
WO2004013160A2 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2004106488A2 (en) * 2003-05-12 2004-12-09 Potomac Pharmaceuticals, Inc. Gene expression suppression agents
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
CA2564988A1 (en) * 2004-04-29 2005-10-29 Yale University Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
EP3153525A1 (de) 2005-03-23 2017-04-12 Genmab A/S Antikörper gegen cd38 zur behandlung von multiplem myelom
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
JP4911915B2 (ja) 2005-05-09 2012-04-04 トヨタ自動車株式会社 標的物の分解方法及び分解装置
AU2006302245A1 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
EP2392646A1 (de) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20090191597A1 (en) * 2006-01-20 2009-07-30 Asklepios Biopharmaceutical, Inc. Enhanced production of infectious parvovirus vectors in insect cells
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
AU2007223427A1 (en) 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
EP3034083B1 (de) 2006-09-21 2020-12-09 University of Rochester Antisense-oligonukleotide zur behandlung von myotoner dystrophie
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
BRPI0720038A2 (pt) * 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US9493817B2 (en) 2007-03-05 2016-11-15 Genesis Research Institute, Inc. Decomposition method and decomposition apparatus for nucleic acid polymer
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010538005A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
US8501912B2 (en) * 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US9241898B2 (en) 2008-03-11 2016-01-26 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
JP2011517410A (ja) * 2008-04-08 2011-06-09 アミリス バイオテクノロジーズ， インコーポレイテッド 異種配列の発現
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
EP2370080A1 (de) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 als zieltherapeutikum bei herzkrankheiten
US20110318738A1 (en) 2008-12-23 2011-12-29 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2010151638A1 (en) 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110274745A1 (en) 2009-11-10 2011-11-10 Lipella Pharmaceuticals Inc. Instillation of liposomal formulation of sirna and antisense oligonucleotides
WO2011082231A1 (en) 2009-12-31 2011-07-07 New York University Compositions and methods for promoting epithelialization and wound closure
WO2011088081A1 (en) 2010-01-12 2011-07-21 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
WO2012082494A2 (en) 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2013044116A1 (en) 2011-09-21 2013-03-28 Yale University Antimicrobial compositions and methods of use thereof
CN102568437B (zh) 2012-01-20 2014-07-30 华为终端有限公司 图像显示方法及设备
CN104797593B (zh) 2012-09-28 2020-05-08 北卡罗来纳-查佩尔山大学 靶向少突胶质细胞的aav载体
US9447433B2 (en) 2013-03-15 2016-09-20 The University Of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
IL293294B2 (en) 2013-03-15 2023-04-01 Univ North Carolina Chapel Hill Methods and compounds for ligation of paired aav glycan vectors
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
CN107206100B (zh) 2014-10-27 2021-02-12 弗罗里达中央大学研究基金会 自然杀伤细胞的方法和组合物
KR20170086537A (ko) 2014-11-21 2017-07-26 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 중추 신경계에 표적화된 aav 벡터
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
CN107531774B (zh) 2015-02-06 2021-12-14 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
MX2017010698A (es) 2015-02-20 2018-04-30 Univ Texas Metodos y composiciones para chlamydia atenuada como vacuna y vector.
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
CN114606267A (zh) 2015-09-28 2022-06-10 北卡罗来纳-查佩尔山大学 逃避抗体的病毒载体的方法和组合物
MX2018007237A (es) 2015-12-14 2018-12-11 Univ North Carolina Chapel Hill Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
EP3449250B1 (de) 2016-04-28 2020-11-04 Indiana University Research & Technology Corporation Verfahren und zusammensetzungen zur auflösung von komponenten einer viruspräparation
EP3496736A4 (de) 2016-08-03 2020-05-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gegen tlr9 gerichtete therapeutika
WO2018050656A2 (en) 2016-09-16 2018-03-22 Hsf Pharmaceuticals Inhibitors of heat shock factors and uses thereof
EP3610023B1 (de) 2017-03-15 2023-10-04 The University of North Carolina at Chapel Hill Polyploide adeno-assoziierte virusvektoren und verfahren zur herstellung und verwendung davon
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
WO2019060538A1 (en) 2017-09-20 2019-03-28 The Trustees Of Indiana University METHODS FOR LIPOPROTEIN RESOLUTION BY MASS SPECTROMETRY
US11232941B2 (en) 2018-01-12 2022-01-25 The Trustees Of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
US20210363191A1 (en) 2018-04-03 2021-11-25 Stridebio, Inc. Antibody-evading virus vectors
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
AU2019247191A1 (en) 2018-04-03 2020-10-15 Ginkgo Bioworks, Inc. Virus vectors for targeting ophthalmic tissues
AU2019281255B2 (en) 2018-06-04 2023-01-12 The Trustees Of Indiana University Ion trap array for high throughput charge detection mass spectrometry
WO2019236140A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Charge detection mass spectrometry with real time analysis and signal optimization
WO2019236139A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
KR102740725B1 (ko) 2018-06-04 2024-12-09 더 트러스티즈 오브 인디애나 유니버시티 정전기 선형 이온 트랩에서 이온을 포획하기 위한 장치 및 방법
WO2019236143A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
WO2019241324A1 (en) 2018-06-12 2019-12-19 The University Of North Carolina At Chapel Hill Synthetic liver-tropic adeno-associated virus capsids and uses thereof
EP3810782A2 (de) 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vektoren zur genfreisetzung, die in zellen persistieren
AU2019354965B2 (en) 2018-10-04 2025-03-27 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
AU2019384065B2 (en) 2018-11-20 2024-12-12 The Trustees Of Indiana University Orbitrap for single particle mass spectrometry
EP4443473A3 (de) 2018-12-03 2025-01-01 The Trustees of Indiana University Vorrichtung zur gleichzeitigen analyse mehrerer ionen mit einer elektrostatischen linearen ionenfalle
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
WO2020219527A1 (en) 2019-04-23 2020-10-29 The Trustees Of Indiana University Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
CA3137106A1 (en) 2019-04-26 2020-10-29 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
AU2020356396A1 (en) 2019-09-25 2022-04-14 The Trustees Of Indiana University Apparatus and method for pulsed mode charge detection mass spectrometry
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
JP7607355B2 (ja) 2020-02-03 2024-12-27 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 電荷検出質量分析用信号の時間ドメイン分析
US12209251B2 (en) 2020-05-05 2025-01-28 The University Of North Carolina At Chapel Hill Modified adeno-associated virus 5 capsids and uses thereof
TW202227632A (zh) 2020-08-19 2022-07-16 美商史崔德生物公司 用於治療雷特症候群之腺相關病毒載體
AU2021369480A1 (en) 2020-10-28 2023-04-20 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
JP2025504263A (ja) 2021-12-23 2025-02-10 ユニバーシティ オブ ロチェスター 内耳への薬剤の送達のためのｃｓｆ輸送経路
US20250073354A1 (en) 2021-12-23 2025-03-06 University Of Rochester Compositions and methods for delivery of agents to inner ear
WO2023150687A1 (en) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors, and methods of use thereof
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JP2703893B2 (ja) * 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
GB2213684A (en) * 1987-12-11 1989-08-16 Philips Electronic Associated Data demodulator baud clock phase locking
RO114469B1 (ro) * 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
EP0400047B1 (de) * 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modifizierte hepatozyten und deren anwendung
EP0339842B1 (de) * 1988-04-27 1996-11-06 Isis Pharmaceuticals, Inc. Oligoribonukleotid-Derivate und ihre Anwendung als antivirale Mittel
EP0380656A1 (de) * 1988-08-16 1990-08-08 Yale University Defiziente hepadna-viren, produktive zellinie für impfstoffe sowie behandlung von erkrankungen und störungen der leber
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5624824A (en) * 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
WO1991016420A1 (en) * 1990-04-20 1991-10-31 The General Hospital Corporation Methods of preventing viral replication
EP0527844B1 (de) * 1990-05-07 1994-08-24 Anchor Hocking Packaging Co. Zusammengesetzter Verschluss
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
CA2117903C (en) * 1992-04-28 1999-01-12 Yan Yuan Targeted cleavage of rna using eukaryotic ribonuclease and external guide sequence
JP3595841B2 (ja) * 1992-12-04 2004-12-02 サーナ セラピューティクス，インコーポレイテッド リボザイム増幅診断用薬
WO1994013791A1 (en) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
IL108206A0 (en) * 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
US6012375A (en) * 1993-07-06 2000-01-11 Eckstein; Donald B. Aircraft infrared guided defense missile system
WO1995023225A2 (en) * 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
AU4961996A (en) * 1994-12-14 1996-07-03 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna

Also Published As

Publication number Publication date
AU2116595A (en) 1995-09-25
US5869248A (en) 1999-02-09
JPH10508181A (ja) 1998-08-18
CA2185117A1 (en) 1995-09-14
EP0748383A1 (de) 1996-12-18
EP0748383B1 (de) 1999-09-15
WO1995024489A1 (en) 1995-09-14
AU696138B2 (en) 1998-09-03
ATE184649T1 (de) 1999-10-15
US5728521A (en) 1998-03-17
DE69512219T2 (de) 2000-01-20

Similar Documents

Publication Publication Date Title
DE69512219D1 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
EP0638121A1 (de) Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz.
AR245776A1 (es) Metodo para la modificacion de las caracteristicas de expresion de un gen endogeno de un microorganismo o una linea celular determinada.
ATE267866T1 (de) Kurze externe führungssequenzen
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
DE69620906D1 (de) Antisense-oligonukleotidmodulation der raf-genexpression
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
HK1073660A1 (en) Methods and compositions and rna interference
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
ATE507300T1 (de) Rekombinante konstrukte und ihre verwendung bei der reduzierung der genexpression
WO2004033620A3 (en) Methods and compositions for therapeutic use of rna interference
DK1017803T3 (da) Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
DE69125374D1 (en) Endonukleasen
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
WO1999063101A3 (en) Transfected cells and methods for treating diabetes
BR9904449A (pt) Processo para o preparo de ácido pantotênico através de amplificação de sequências de nucleotìdeos, as quais codificam a redutase de cetopantoato
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
DE69738753D1 (de) AUF TGF-beta 1 ANSPRECHENDE KNOCHENMARKZELLEN
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
AR016680A2 (es) Novedosas toxinas pesticidas y secuencias de polinucleotidos que codifican estas toxinas
NO20000576L (no) Blanding og fremgangsmåte for regulering av celleproliferasjon og celledød
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
Yuan et al. Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
DE60130465D1 (de) Mutierte muskelspezifische enhancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee